The answer may surprise you.
The answer may surprise you.
Ramón Laureano hit the first of Oakland's four homers and Frankie Montas pitched six effective innings, helping the Athletics beat the sliding Minnesota Twins 6-1 on Friday night. Sean Murphy and Stephen Piscotty each hit a two-run shot, and Mark Canha contributed a pinch-hit homer. The Athletics have won five of seven.
Big Tech needs to take more decisive action against the "Disinformation Dozen," says the group that identified them.
In at least one case a child was kept on a coach for four days, waiting to join his family.
NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. f/k/a Conversion Labs, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-04004, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired LifeMD securities between January 19, 2021 and April 13, 2021, inclusive (the “Class Period”). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the “Exchange Act”). If you are a shareholder who purchased LifeMD securities during the Class Period, you have until June 15, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at email@example.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] LifeMD is a direct-to-patient telehealth company. It offers a telemedicine platform that purports to help patients access licensed providers for diagnoses, virtual care, and prescription medications. The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) many of LifeMD’s executives were associated with Redwood Scientific Technologies, Inc. (“Redwood Scientific”) when it was charged for unlawful autoshipping, abusive telemarketing, and false claims, and that they employed similar practices at the Company; (ii) LifeMD engaged in autoshipping products to unwilling customers to record recurring revenue and the Company made it difficult to cancel such subscriptions; (iii) certain of the purportedly licensed physicians on the Company’s platform were not in fact licensed and faced disciplinary action; (iv) as a result of the foregoing practices, the Company was reasonably likely to face regulatory scrutiny and/or reputational harm; and (v) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On April 14, 2021, Culper Research (“Culper”) issued a report alleging that “LifeMD appears to use unlicensed doctors to dispense OTC medications, has implemented an autoshipping/autobilling scheme, failed to honor guarantees, and put in place abusive telemarketing practices.” The report also alleged that several of the Company’s executives were involved in “wide ranging fraud” at Redwood Scientific, which was charged by the U.S. Federal Trade Commission for “unlawful autoshipping, abusive telemarketing, and false claims.” Specifically, according to Culper, “many customers are effectively duped into purchasing subscriptions rather than one-time purchases” and LifeMD “makes cancellations difficult if not impossible.” On this news, the Company’s share price fell $2.84, or 24%, to close at $9.00 per share on April 14, 2021, on unusually heavy trading volume. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980
David Peterson had his best outing as a major leaguer on Friday. But it was all for naught, as the Mets fell to the Rays 3-2 in walk-off fashion.
May 14—Some Coos County families are temporarily out of childcare. Bay Area Hospital's Bright Beginnings Learning Center has suspended classes after a large share of its staff resigned earlier this month, according to a hospital executive. Eight or nine teachers at the center resigned at the same time as the center's director, according to Clay England, chief human resources officer, who ...
St. John's Northwestern Academies (SJNA) announced today that it has achieved the $2 million fund raising goal for The Rick Leone Challenge Match Campaign nearly one month ahead of the Campaign's original end date of May 31st. The Campaign consisted of an initial $1 million challenge match by Mr. John Leone along with matching contributions of $1million. The Rick Leone Challenge Match Campaign is named in honor of Mr. Leone's son Rick, who was a graduate from the Class of 1975. To date, the Campaign boasts over 200 donors including 100% participation by SJNA's Board of Trustees. "Rick Leone was an inspiration to all who knew him," said Michael Henn, Board Chair of SJNA. "The Academy is truly grateful to Mr. Leone all those who donated in Rick's honor for this critically needed support for our beloved Academy."
CHICAGO — Michael Kopech pitched four strong innings and Andrew Vaughn hit a two-run home run as the Chicago White Sox beat the Kansas City Royals 3-1 in Game 2 of a split doubleheader Friday. Kopech allowed one run on two hits with five strikeouts and two walks as the Sox earned a split in front of 9,823 at Guaranteed Rate Field. The Royals won the first game, 6-2. The Sox were without first ...
Even with the lost, David Peterson still had a solid outing, including a stretch he set down 17 Rays in a row. Peterson discussed what helped him retire 17 Rays in a row, and credited the defense behind him: 'Those guys never fail to bring their best effort'
First Quarter 2021 Managed Case Volume Increased 34% to 2,794DENVER, May 14, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Assure Holdings Corp. (TSXV: IOM; OTCQB: ARHH), the CONDENSED INTERIM CONSOLIDATED STATEMENT OF INCOME/(LOSS) table was omitted and the financial tables were not aligned with the appropriate headings. These issues have been corrected in this version. No changes were made to any financial data or text in this announcement. The corrected release follows: Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), reported financial results for the first quarter ended March 31, 2021. Management Commentary “Assure made significant planned investments in the first quarter to build the organizational infrastructure necessary for supporting dramatically expanding scale driven by organic and M&A growth, launching a telehealth offering for professional neurology services, delivering exceptional quality of service to the surgeons we support, building an industry-leading revenue cycle management function and adding competencies that effectively differentiate the Company from IONM peers,” said John A. Farlinger, Assure’s executive chairman and CEO. “On the back of our first quarter investments, we are already beginning to experience the lift in procedure volume anticipated in the second quarter, as Assure focused on completing and integrating recent acquisitions. We expect our procedure volume to accelerate substantially in the second half of the year, as we execute against our key corporate objectives: scaling our platform through both organic growth and M&A, development of an in-network revenue stream, improving the performance of Assure’s billing and collections function and becoming recognized clinical care leaders in the IONM industry.” “We raised our guidance for full-year 2021 total procedures to 17,000, representing an anticipated increase in cases of more than 70% compared with 2020 and an increase of 165% since 2019. This reflects our confidence in continued strong organic growth and pro-rated contributions from two Texas-based IONM companies, Sentry Neuromonitoring and Elevation, that Assure acquired in the second quarter of 2021. This guidance excludes any potential M&A in the second half of the year. In 2020, Sentry performed more than 5,500 IONM procedures and Elevation performed approximately 550. These acquisitions are consistent with our strategic plan to create scale by augmenting our organic growth with accretive M&A opportunities. In both cases, Assure’s existing presence in Texas provided the Company with valuable insight on how we can maximize surgeon relationships to win new business, improve historic collections on a per procedure basis and leverage scale to negotiate new in-network agreements with payors in the local market. The acquisition of Sentry also facilitated the expansion of our operational footprint to ten states with the addition of Missouri and Kansas, where Sentry has existing operations. We believe that the final terms for these acquisitions were favorable from a payment schedule and cost of capital perspective.” “Another contributor to growth in 2021 and beyond is expected to come from our recent expansion into telehealth through the launch of professional neurology services for IONM. The offering is a straightforward transition as we replace a third-party vendor with professional services furnished through a wholly owned subsidiary. Providing telehealth neurology services on our own platform should allow Assure to control quality of service in all aspects of our IONM offering, which is a key consideration for payors as we negotiate new in-network agreements. Additionally, offering telehealth services strengthens our offering as we position to sell directly to hospitals and enhances continuity with the surgeons we support. It also facilitates the capture of a greater share of revenue and margin on each IONM procedure in our existing operations and positions Assure to drive new organic growth. We are already performing cases with the initial roll-out focused on providing telehealth neurology services to Assure patients, and we ultimately expect to expand and support other IONM providers and hospitals. Further, we intend to market this offering to doctors and medical groups that need telehealth neurology services associated with epilepsy, electroencephalogram (EEG) and sleep disorders, among other services.” “Assure is continuing to drive cash collections improvements that began when we brought revenue cycle management in-house after we terminated a legacy 3rd party vendor due to poor performance. We made investments to accelerate collections by automating a process that had previously been almost entirely manual and to develop and improve our in-network revenue stream. Nearly 30% of Assure’s overall commercial insurance volume is now in contractual rates, either directly or indirectly with payors, helping to reduce risk, minimize complexity, protect our liquidity and accelerate the timing of payments. Additionally, we recently announced the signing of an in-network insurance agreement with Aetna Colorado and are in active negotiations with numerous other potential partners.” “Assure is entering the next phase of growth and evaluating a number of promising opportunities that have the potential to significantly drive meaningful top-line growth and market share capture in 2021 and beyond. These investments require a certain amount of upfront spending, including to open new markets, but we believe that the scale we will be gaining will have a substantial and highly favorable impact on our profitability in the future. I am confident our team will continue to successfully execute the Company’s growth plans as we prepare for a potential uplisting to a major U.S. exchange later this year.” Assure will be filing its quarter-end financial statements with SEDAR and the SEC at www.sedar.com, www.sec.gov and the Company website. First Quarter 2021 Financial Highlights vs. First Quarter 2020 (All currency reported in U.S. Dollars) Total revenue was $4.8 million versus $4.3 million.Managed cases increased 34% to 2,794 versus 2,087.General and administrative expenses were $3.1 million compared to $2.2 million, reflecting our investments to build Assure’s management team and professional fees related to financial transactions, SEC registration (S-1) and reporting and acquisitions.Net loss of $(1.2) million compared to net loss of $(0.4) million.Net loss per diluted share of $(0.02) compared to net loss of $(0.01) per diluted share.Adjusted EBITDA was $(1.0) million versus $0.2 million.The Company collected $6.1 million compared to $5.8 million for a combination of technical IONM services and cash collected from PEs for professional IONM services.The Company collected $3.1 million versus $3.0 million for IONM revenue that it retains 100%.In March 2021, Assure received a $1.7 million second draw loan provided under the United States Small Business Administration Paycheck Protection Program pursuant to the Coronavirus Aid, Relief, and Economic Security Act. Assure anticipates that all or a portion of the loan will be forgiven as the Company expects to maintain its employment and compensation within designated parameters. Operational Guidance The Company forecasts 17,000 total procedures for full-year 2021, a record number representing an increase of more than 70% compared with 2020. This projection is based on organic growth and the acquisitions of Sentry Neuromonitoring and Elevation. It does not account for the impact from anticipated M&A activity that may occur in the second half of 2021. In addition, the guidance reflects the impact to-date of COVID-19, but not a substantial future disruption relating to the pandemic. Subsequent Events: Completed Acquisition of Sentry Neuromonitoring and Elevation LP and Debt Settlement Agreement In April 2021, Assure completed the previously announced acquisition of all assets (the “Acquisition”) of Sentry Neuromonitoring (“Sentry”), one of the largest IONM service providers in Texas. The acquisition of Sentry had four primary impacts: First, it strengthened and diversified Assure’s revenue stream with a substantial increase in number of procedures. Second, it expanded Assure’s scale in Texas, which the Company expects will create more opportunity for in-network negotiations with insurance companies. Third, it expanded Assure’s reach with the addition of Missouri and Kansas, where Sentry has existing operations. Fourth, it is anticipated to be accretive in 2021 and beyond. In 2020, on an unaudited basis, Sentry generated approximately $5 million of incremental cash receipts from revenue. Sentry’s total number of procedures was approximately 5,500 in 2020. Assure paid US$3,500,000 to Sentry (the “Purchase Price”) as consideration for the Acquired Assets. The Purchase Price is payable as follows: (i) a cash payment of US$1,225,000, payable over a three-year period, and (ii) the issuance of 1,660,583 common shares in the capital of the Company (the “Common Shares”) at a deemed price of US$1.37 per share. In addition, in March 2021, Assure acquired the assets of Elevation EP, LLC (“Elevation”), a Texas-based IONM service provider. In 2020, Elevation performed approximately 550 IONM procedures. The Company also announces that it has entered into an agreement to issue 75,000 Common Shares at a deemed value of $1.53 per share to settle an outstanding debt with an arm’s length service provider (the “Debt Settlement”). The Common Shares are subject to a hold period in accordance with applicable Canadian and U.S. securities laws. The Debt Settlement was conditionally accepted by the TSX Venture Exchange (“TSXV”) on May 3, 2021. The Company submitted an initial listing application to list on Nasdaq. Conference Call The Company will hold a conference call today, May 14, 2021, at 12:00 p.m. Eastern time to discuss its first quarter 2021 results. Date: Friday, May 14, 2021Time: 12:00 p.m. Eastern time (10:00 a.m. Mountain time)Toll-free dial-in number: 1-877-407-0792International dial-in number: 1-201-689-8263Conference ID: 13719448 Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will be broadcast live and available for replay here. A replay of the conference call will be available after 3:00 p.m. Eastern time on the same day through May 28, 2021. Toll-free replay number: 1-844-512-2921International replay number: 1-412-317-6671Replay ID: 13719448 Non-GAAP Measures This press release includes certain measures which have not been prepared in accordance with Generally Accepted Accounting Principals (“GAAP”) such as Adjusted EBITDA, case volume, cases and managed cases. The non-GAAP measures presented are unlikely to be comparable to similar measures presented by other issuers. References to Adjusted EBITDA are to net income/(loss) excluding interest, taxes, depreciation and amortization, share-based compensation, gain on payroll protection program loan and gain on extinguishment of acquisition debt. Reference to case volume, cases and managed cases are to procedures monitored by the Company. None of the foregoing non-GAAP measures is an earnings measure recognized by GAAP and do not have a standardized meaning prescribed by GAAP. Management believes that Adjusted EBITDA, case volume, managed cases and cases are appropriate measures in evaluating the Company’s performance. Readers are cautioned that Adjusted EBITDA, managed cases, case volume and cases should not be construed as alternatives to net income (as determined under GAAP), as indicators of financial performance or to cash flow from operating activities (as determined under GAAP) or as measures of liquidity and cash flow. About Assure Holdings Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned The Joint Commission’s Gold Seal of Approval®. For more information, visit the Company’s website at www.assureneuromonitoring.com. Forward-Looking Statements This news release may contain “forward-looking statements” within the meaning of applicable securities laws, including, but not limited to: the Company’s expansion and financing and M&A plans; the Company’s revenue and cash flow; the collection of outstanding amounts owed to the Company; comments with respect to strategies, expectations, planned operations and future actions of the Company; the maximization of the Company’s in-network revenue; the Company’s expansion into telehealth and the anticipated effects thereof; plans to uplist to a major U.S. exchange; the rescheduling of postponed procedures; the Company’s accounting practices; the impact of COVID-19; the total number of procedures for 2021; collections of accounts receivable including a meaningful share of the 2018 reserved receivables and the Acquisition and the expected effects thereof. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "plans," "should," "could," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s revenue accrual rates may experience significant decline in 2021; the Company may not increase its scale and expand into new states in 2021; the Company’s ability to successfully expand; the Company may not improve its revenue and cash flow; the Company’s ability to collect past due accounts receivable; the accuracy of the reservations made to receivables; the Company may not be able to maximize the Company’s in-network revenue and negotiate new in-network agreements; the Company’s expansion into telehealth may not result in the negotiation of new in-network agreements and strengthen the Company’s position to sell directly to hospitals; the Company may not perform 17,000 procedures in 2021; the TSX Venture exchange may not approve the Debt Settlement; all or a portion of the $1.7 million Loan may not be forgiven; the Company may not maintain its employment and compensation framework within the parameters of the Coronavirus Aid, Relief, and Economic Security Act; the Company’s decision to further reduce its accrual rate and revenue per procedure expectations may not reduce its down-side risk; uncertainties related to market conditions and our ability to qualify for a listing on Nasdaq; the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and economic activity in general; and the risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com and those included in the Company’s registration statement on Form S-1 filed with the United States Securities and Exchange Commission and available at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Scott Kozak, Investor and Media RelationsAssure Holdings Corp.1-720-287-3093Scott.Kozak@assureiom.com SCHEDULE A ASSURE HOLDINGS CORP.CONDENSED INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION(in thousands of United States Dollars) March 31, 2021 (unaudited) December 31, 2020ASSETS Current assets Cash $4,080 $4,386 Accounts receivable, net 15,710 14,965 Income tax receivable 150 150 Other assets 807 618 Due from PEs 5,031 4,856 Total current assets 25,778 24,975 Equity method investments 416 608 Property, plant and equipment, net 305 356 Operating lease right of use asset 67 124 Finance lease right of use asset 764 608 Intangibles, net 3,998 4,115 Goodwill 2,857 2,857 Total assets $34,185 $33,643 LIABILITIES AND SHAREHOLDERS' EQUITY LIABILITIES Current liabilities Accounts payable and accrued liabilities $2,934 $2,871 Current portion of debt 4,100 4,100 Current portion of lease liability 623 521 Other current liabilities 72 96 Total current liabilities 7,729 7,588 Lease liability, net of current portion 789 772 Debt, net of current portion 4,011 2,251 Acquisition share issuance liability 540 540 Fair value of stock option liability 19 16 Performance share issuance liability 2,081 2,668 Deferred tax liability, net 172 599 Total liabilities 15,341 14,434 SHAREHOLDERS' EQUITY Common stock 56 56 Additional paid-in capital 31,707 30,841 Retained earnings (deficit) (12,919) (11,688)Total shareholders' equity 18,844 19,209 Total liabilities and shareholders' equity $34,185 $33,643 ASSURE HOLDINGS CORP.CONDENSED INTERIM CONSOLIDATED STATEMENT OF INCOME/(LOSS)(in thousands of United States Dollars, except per share amounts) Three Months Ended March 31, 2021 2020 (unaudited) (unaudited)Revenue Patient service fees, net $2,950 $2,346 Hospital, management and other 1,815 1,987 Total revenue 4,765 4,333 Cost of revenues 2,532 1,798 Gross margin 2,233 2,535 Operating expenses General and administrative 3,132 2,246 Sales and marketing 335 221 Depreciation and amortization 285 259 Total operating expenses 3,752 2,726 Loss from operations (1,519) (191)Other income/(expenses) Earnings/(loss) from equity method investments (23) (107)Other income/(expense) (3) 57 Accretion expense (95) (185)Interest, net (18) (53)Total other expense (139) (288)Loss before income taxes (1,658) (479)Income tax benefit 427 65 Net loss $(1,231) $(414)Basic loss per common share $(0.02) $(0.01)Diluted loss per common share $(0.02) $(0.01) ASSURE HOLDINGS CORP.RECONCILIATION OF NON-GAAP ADJUSTED EBITDA TO NET LOSS (in thousands of United States Dollar Three Months Ended March 31, 2021 2020 (unaudited) (unaudited)Reported net income (loss)$(1,231) $(414)Interest, net 18 53 Accretion expense 95 185 Depreciation and amortization 285 259 Share based compensation 279 205 Income tax expense (benefit) (427) (65)Provision for stock option fair value 3 (57) $(978) $166 ASSURE HOLDINGS CORP.EARNINGS PER SHARE(in thousands of United States Dollars, except per share amounts) Three Months Ended March 31, 2021 2020 Net loss$(1,231) $(414)Basic weighted average common shares outstanding 56,537,711 34,795,313 Basic loss per common share$(0.02) $(0.01)Net loss$(1,231) $(414)Dilutive weighted average common shares outstanding 56,537,711 34,795,313 Diluted earnings (loss) per common share$(0.02) $(0.01)
Universal Orlando and Disney World said Friday that guests will no longer be required to wear masks while outdoors starting Saturday at the parks.
Just days after Season 19 finalist Caleb Kennedy was cut from American Idol when a racially insensitive video surfaced, Season 18 fan favorite Doug Kiker — known as the “singing garbageman” – has been arrested on domestic violence charges in Alabama. Kiker was booked on Thursday for domestic violence, per the Mobile County Sheriff’s Office […]
NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amdocs Limited (“Amdocs” or the “Company”) (NASDAQ: DOX), and certain of its officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 21-cv-03078, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Amdocs ordinary shares between December 13, 2016 and March 30, 2021, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. If you are a shareholder who purchased Amdocs ordinary shares during the Class Period, you have until June 8, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at firstname.lastname@example.org or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. [Click here for information about joining the class action] Amdocs, through its global subsidiaries, provides software and services to communications, cable and satellite, entertainment, and media industry service providers worldwide. Historically, the Company’s largest percentage of revenues come from its North American business, mostly the U.S., particularly from large customers including, among others, AT&T Inc. (“AT&T”). The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (ii) Amdocs concealed its large borrowing; (iii) while Amdocs’ reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. On March 31, 2021, pre-market, Jehoshaphat Research published a short-seller report addressing Amdocs, which alleged, inter alia, that Amdocs overstated its profits, evidenced by steady parent profits despite declining subsidiary profits; that there was a concerning pattern of reputable auditors resigning, only to be replaced by “scandal-plagued or tiny shops”; that Amdocs “window-dressed” its balance sheets to keep its large borrowing a secret, namely by paying down its debt just prior to the end of each quarter, therefore showing a debt-free balance sheet on that day, before re-borrowing the money shortly thereafter; and that all of the foregoing was corroborated by former employees and direct competitors of the Company, who noted that Amdocs was losing AT&T as a customer, as well as a former American Amdocs executive, who stated that the Company’s “US business was declining at a rate of [around] 7% annually . . . but then we would see the company [publish results that] say North America is stable.” On this news, Amdocs’ ordinary share price fell $9.19 per share, or 11.58%, to close at $70.15 per share on March 31, 2021. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980
Toronto, Ontario--(Newsfile Corp. - May 14, 2021) - Aurelius Minerals Inc. (TSXV: AUL) (the "Company" or "Aurelius") announces that it has closed the final tranche of its previously announced non-brokered private placement offering (the "Offering") for additional gross proceeds of $510,000 including (i) 400,000 common shares of the Company ("Common Shares") on a post consolidation basis for gross proceeds of $240,000, and (ii) 400,000 common shares which qualify as "flow-through shares" (as defined in ...
Led by goals from seniors Caroline Pulliam and Caileen Almeida, Myers Park’s girls soccer team won its first NCHSAA state title
Airport ‘shocked and saddened’ by scrap outside duty free
The NBC News correspondent began covering NASA in 1957 when the agency was struggling with a series of humiliating explosions.
May 14—After reducing the bond to $1 million last month for a West Toledo man accused of fatally shooting a man and injuring two others at the Georgetown Village Apartments, a Lucas County judge granted a request Friday to accept property value for the man's release from jail. On April 15, Judge Eric Marks granted defense attorney Ronnie Wingate's request to reduce bond for his client, ...